Needham & Company LLC Reiterates Hold Rating for TransMedics Group (NASDAQ:TMDX)

Needham & Company LLC reissued their hold rating on shares of TransMedics Group (NASDAQ:TMDX) in a report issued on Friday, Marketbeat Ratings reports. They currently have a $109.00 price target on the stock.

A number of other equities analysts also recently issued reports on the company. JPMorgan Chase & Co. lowered their price target on TransMedics Group from $173.00 to $116.00 and set an “overweight” rating on the stock in a research report on Tuesday, October 29th. Baird R W upgraded TransMedics Group to a “strong-buy” rating in a research report on Tuesday, September 24th. Piper Sandler cut their price target on shares of TransMedics Group from $180.00 to $110.00 and set an “overweight” rating for the company in a report on Wednesday, November 20th. Oppenheimer reduced their price objective on shares of TransMedics Group from $200.00 to $125.00 and set an “outperform” rating for the company in a research report on Tuesday, October 29th. Finally, TD Cowen dropped their target price on shares of TransMedics Group from $175.00 to $120.00 and set a “buy” rating on the stock in a research report on Monday, November 18th. Two investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, TransMedics Group currently has an average rating of “Moderate Buy” and an average target price of $131.80.

TransMedics Group Price Performance

NASDAQ:TMDX opened at $76.04 on Friday. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33. The company has a 50 day moving average price of $119.18 and a 200-day moving average price of $137.84. TransMedics Group has a 1-year low of $67.77 and a 1-year high of $177.37. The firm has a market cap of $2.55 billion, a price-to-earnings ratio of 80.89 and a beta of 2.08.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings results on Monday, October 28th. The company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.29 by ($0.17). The firm had revenue of $108.76 million for the quarter, compared to analyst estimates of $115.00 million. TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The firm’s quarterly revenue was up 63.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.12) EPS. Equities research analysts forecast that TransMedics Group will post 1 EPS for the current year.

Insiders Place Their Bets

In related news, CEO Waleed H. Hassanein sold 8,625 shares of the stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $153.42, for a total value of $1,323,247.50. Following the completion of the sale, the chief executive officer now owns 61,643 shares of the company’s stock, valued at approximately $9,457,269.06. This trade represents a 12.27 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Nicholas Corcoran sold 10,000 shares of TransMedics Group stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $176.02, for a total value of $1,760,200.00. Following the transaction, the insider now owns 21,105 shares in the company, valued at approximately $3,714,902.10. The trade was a 32.15 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 36,958 shares of company stock valued at $5,230,528 in the last 90 days. 7.00% of the stock is owned by insiders.

Institutional Trading of TransMedics Group

Several large investors have recently added to or reduced their stakes in TMDX. International Assets Investment Management LLC purchased a new position in shares of TransMedics Group during the 2nd quarter worth $47,000. USA Financial Formulas acquired a new stake in TransMedics Group during the third quarter worth about $55,000. Quarry LP boosted its holdings in TransMedics Group by 557.1% in the 3rd quarter. Quarry LP now owns 368 shares of the company’s stock valued at $58,000 after purchasing an additional 312 shares during the last quarter. National Bank of Canada FI boosted its holdings in TransMedics Group by 174.7% in the 3rd quarter. National Bank of Canada FI now owns 412 shares of the company’s stock valued at $65,000 after purchasing an additional 262 shares during the last quarter. Finally, J.Safra Asset Management Corp grew its stake in shares of TransMedics Group by 649.2% in the 2nd quarter. J.Safra Asset Management Corp now owns 442 shares of the company’s stock valued at $67,000 after buying an additional 383 shares during the period. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.